FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4309189258> ?p ?o ?g. }

• W4309189258 endingPage "A022" @default.
• W4309189258 startingPage "A022" @default.
• W4309189258 abstract "Abstract Optimal management of patients with potentially resectable pancreatic ductal adenocarcinoma (PDAC) is controversial and variation exists within/across academic and healthcare systems. Herein we describe the initial results of a neoadjuvant therapy (NAT) pathway across one of New York’s largest, most diverse health care systems. The NATP was established at Northwell Health in June 2019, consisting of an initial, single-day pancreas multi-disciplinary clinic (PMDC) visit, followed by NAT, interval scans and PMDC re-reviews at two and four months, prior to consideration of radiation and of surgical resection. We conducted an IRB-approved retrospective analysis of patients enrolled to this pathway. Primary endpoints included completion of NAT pathway and overall survival (OS). Kaplan-Meier analysis was used to estimate OS. The cohort consisted of 55 patients: 44% men, mean age 69.7 years, and 48% non-White. Surgical stage at diagnosis was locally advanced (LAPC; 49%), borderline resectable (BRPC; 35%) and resectable (RPC; 16%). NAT consisted of gemcitabine/nab-paclitaxel (GnP, 41%; 147 total cycles), FOLFIRINOX (36%; 167 total cycles), and a combination of both regimens (23%). Eighteen (33%) received radiotherapy (94%, SBRT) and 72% received &gt;=50 Gy. Average duration of NAT pathway (from biopsy to surgery) was 5.9 mo (IQR 4.7-7.6 mo): average time from biopsy to C1 of NAT was 25 days (IQR 18-39 days), from C1 to post NAT completion imaging was 3.9 mo (IQR 3.5-4.8 mo) and from RT to surgery was 36.0 days (IQR 30.5-43.8 days). Of 55 patients who began the pathway, 24 (44%; 6% RPC, 53% BRPC, 41% LAPC) completed the pathway and underwent surgical exploration; 22 did not complete the pathway and 9 are currently undergoing NAT. Reasons for not completing NAT included metastasis (24%), transfer of care (12%), local progression (5.5%), and death (3.6%). Out of 24 patients who were surgically explored, 71% underwent successful resection (53% R0, 18% R1&lt;1mm and 30% R1) compared to prior institutional resection rate in NAT patients of 17% (p=0.015). There were 11 deaths (20%) and median OS was reached at 17.7 mo (95% CI 7.9, 27.6): 16.3 mo 95% CI 7.2, 25.4) and 26.1 mo (95% CI 3.2, 49) for GnP and FOLFIRINOX, respectively. Patients enrolled in the NAT pathway had a higher rate of germline mutation testing (52% vs 30%, p=0.002). The percentage of patients that remained within the Northwell Health system for their post-NAT was higher among patients in the pathway, compared to prior (87% versus 44%). Implementation of a standardized NAT approach at a large diverse healthcare system increased the percentage of PDAC patients who underwent surgical resection and improved patient retention rate. Citation Format: Ruwan Parakrama, Baho Sidiqi, Lyudmyla Demyan, Shamsher Pasha, Danielle Pinto, Tiffany Zavadsky, Xianghui Zhou, Sunita Patruni, Adrianna Kapusta, Oliver Standring, Matthew J. Weiss, Joseph M. Herman, Daniel A. King. Standardization of a neoadjuvant therapy (NAT) pathway for pancreatic cancer across a geographically large and diverse healthcare system improves patient outcomes and successful completion of NAT [abstract]. In: Proceedings of the AACR Special Conference on Pancreatic Cancer; 2022 Sep 13-16; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2022;82(22 Suppl):Abstract nr A022." @default.
• W4309189258 created "2022-11-24" @default.
• W4309189258 creator A5010547072 @default.
• W4309189258 creator A5011362562 @default.
• W4309189258 creator A5011445697 @default.
• W4309189258 creator A5014748431 @default.
• W4309189258 creator A5018591104 @default.
• W4309189258 creator A5027031589 @default.
• W4309189258 creator A5041736128 @default.
• W4309189258 creator A5045982943 @default.
• W4309189258 creator A5050133619 @default.
• W4309189258 creator A5059086651 @default.
• W4309189258 creator A5059834620 @default.
• W4309189258 creator A5080138924 @default.
• W4309189258 creator A5089299130 @default.
• W4309189258 date "2022-11-15" @default.
• W4309189258 modified "2023-09-29" @default.
• W4309189258 title "Abstract A022: Standardization of a neoadjuvant therapy (NAT) pathway for pancreatic cancer across a geographically large and diverse healthcare system improves patient outcomes and successful completion of NAT" @default.
• W4309189258 doi "https://doi.org/10.1158/1538-7445.panca22-a022" @default.
• W4309189258 hasPublicationYear "2022" @default.
• W4309189258 type Work @default.
• W4309189258 citedByCount "0" @default.
• W4309189258 crossrefType "journal-article" @default.
• W4309189258 hasAuthorship W4309189258A5010547072 @default.
• W4309189258 hasAuthorship W4309189258A5011362562 @default.
• W4309189258 hasAuthorship W4309189258A5011445697 @default.
• W4309189258 hasAuthorship W4309189258A5014748431 @default.
• W4309189258 hasAuthorship W4309189258A5018591104 @default.
• W4309189258 hasAuthorship W4309189258A5027031589 @default.
• W4309189258 hasAuthorship W4309189258A5041736128 @default.
• W4309189258 hasAuthorship W4309189258A5045982943 @default.
• W4309189258 hasAuthorship W4309189258A5050133619 @default.
• W4309189258 hasAuthorship W4309189258A5059086651 @default.
• W4309189258 hasAuthorship W4309189258A5059834620 @default.
• W4309189258 hasAuthorship W4309189258A5080138924 @default.
• W4309189258 hasAuthorship W4309189258A5089299130 @default.
• W4309189258 hasConcept C121608353 @default.
• W4309189258 hasConcept C126322002 @default.
• W4309189258 hasConcept C141071460 @default.
• W4309189258 hasConcept C143998085 @default.
• W4309189258 hasConcept C182516595 @default.
• W4309189258 hasConcept C2777148230 @default.
• W4309189258 hasConcept C2780210213 @default.
• W4309189258 hasConcept C2780258809 @default.
• W4309189258 hasConcept C2780962732 @default.
• W4309189258 hasConcept C31258907 @default.
• W4309189258 hasConcept C41008148 @default.
• W4309189258 hasConcept C509974204 @default.
• W4309189258 hasConcept C526805850 @default.
• W4309189258 hasConcept C71924100 @default.
• W4309189258 hasConcept C72563966 @default.
• W4309189258 hasConceptScore W4309189258C121608353 @default.
• W4309189258 hasConceptScore W4309189258C126322002 @default.
• W4309189258 hasConceptScore W4309189258C141071460 @default.
• W4309189258 hasConceptScore W4309189258C143998085 @default.
• W4309189258 hasConceptScore W4309189258C182516595 @default.
• W4309189258 hasConceptScore W4309189258C2777148230 @default.
• W4309189258 hasConceptScore W4309189258C2780210213 @default.
• W4309189258 hasConceptScore W4309189258C2780258809 @default.
• W4309189258 hasConceptScore W4309189258C2780962732 @default.
• W4309189258 hasConceptScore W4309189258C31258907 @default.
• W4309189258 hasConceptScore W4309189258C41008148 @default.
• W4309189258 hasConceptScore W4309189258C509974204 @default.
• W4309189258 hasConceptScore W4309189258C526805850 @default.
• W4309189258 hasConceptScore W4309189258C71924100 @default.
• W4309189258 hasConceptScore W4309189258C72563966 @default.
• W4309189258 hasIssue "22_Supplement" @default.
• W4309189258 hasLocation W43091892581 @default.
• W4309189258 hasOpenAccess W4309189258 @default.
• W4309189258 hasPrimaryLocation W43091892581 @default.
• W4309189258 hasRelatedWork W1975191131 @default.
• W4309189258 hasRelatedWork W2559093989 @default.
• W4309189258 hasRelatedWork W2599910524 @default.
• W4309189258 hasRelatedWork W2736952847 @default.
• W4309189258 hasRelatedWork W284685154 @default.
• W4309189258 hasRelatedWork W3045328550 @default.
• W4309189258 hasRelatedWork W3154040450 @default.
• W4309189258 hasRelatedWork W3173108227 @default.
• W4309189258 hasRelatedWork W3177534832 @default.
• W4309189258 hasRelatedWork W4307429747 @default.
• W4309189258 hasVolume "82" @default.
• W4309189258 isParatext "false" @default.
• W4309189258 isRetracted "false" @default.
• W4309189258 workType "article" @default.